BRIEF-Eiger completes enrollments for phase 2 in hypoglycemia study
June 06, 2017 at 08:30 AM EDT
* Eiger completes enrollment in phase 2 multiple-ascending dose study of exendin 9-39 in post-bariatric hypoglycemia patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
